Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced the granting of stock options and restricted stock units to 33 new employees on June 30, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced the granting of stock options and restricted stock units to 33 new employees on June 30, 2022. Under the 2017 Inducement Plan, a total of 28,800 stock options and 96,200 restricted stock units were awarded. The stock options have an exercise price of $1.93 and vest over four years, while the restricted stock units will vest fully after 36 months. The awards are part of the company’s strategy to incentivize employee retention and growth.
Positive
- Granting of stock options and restricted stock units may enhance employee retention and motivation.
- Stock options are priced at $1.93, aligning employee interests with shareholder value.
Negative
- None.
Details
News Market Reaction – PRTK
The recorded move for PRTK in the trading session of this news was +2.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on June 30, 2022, the Company granted stock options and restricted stock units to thirty-three new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
The stock options are to acquire, in the aggregate, 28,800 shares of the Company’s common stock at a per share exercise price of
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA. Paratek estimates this opportunity represents a potential
Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), now valued at up to approximately
For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.
CONTACT:
For Investors:
Hans Vitzthum
LifeSci Advisors
ir@ParatekPharma.com
Phone: 617-430-7578
For Media:
Christine Fanelle
Scient PR
christine@scientpr.com
Phone: 215-595-5211
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.